At a glance
- Originator Sankyo
- Class Antihyperlipidaemics
- Mechanism of Action Squalene synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 21 Jul 1997 New profile
- 21 Jul 1997 Preclinical development for Hyperlipidaemia in Japan (Unknown route)